Crystal structure of aminopentamide hydrogen sulfate, (C 19 H 25 N 2 O)(HSO 4 )
Source abstract
Abstract
The crystal structure of aminopentamide hydrogen sulfate has been solved and refined using synchrotron X-ray powder diffraction data, and optimized using density functional techniques. Aminopentamide hydrogen sulfate crystallizes in space group P 2 1 / c (#14) with a = 17.62255(14), b = 6.35534(4), c = 17.82499(10) Å, β = 96.4005(6)°, V = 1983.906(14) Å 3 , and Z = 4. The structure consists of layers parallel to the bc -plane with hydrogen sulfate anions at the core and aminopentamide cations on the outside. There is a strong charge-assisted O49–H53⋯O52 hydrogen bond between the hydrogen sulfate anions. This hydrogen bond links the anions in a chain parallel to the b -axis. The cation forms a discrete N–H⋯O hydrogen bond to the anion. The amide group also forms two weaker discrete hydrogen bonds to the anion. The three N–H⋯O hydrogen bonds link the cations and anions into columns parallel to the b -axis. This commercial material from USP contained an unidentified impurity, the powder pattern of which could be indexed on a monoclinic unit cell. The powder pattern has been submitted to ICDD for inclusion in the Powder Diffraction File™ (PDF®).
Source: crossref · Quality: baseline
Research context
OpenAlex topics: X-ray Diffraction in Crystallography · Crystallography and molecular interactions · Crystal Structures and Properties
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (38)
Show source-provided references
1. 10.1063/1.46788210.1063/1.467882 ↗
2. 2016
3. Wavefunction, Inc. (2020). Spartan ‘18 Version 1.4.5, Wavefunction Inc., 18401 Von Karman Ave., Suite 370, Irvine, CA 92612.
4. 10.1017/S088571561400090610.1017/S0885715614000906 ↗
5. Etudes sur la loi de Bravais
6. 10.1002/anie.19951555110.1002/anie.199515551 ↗
7. Bravais · 1866
8. 10.1107/S010876819901508610.1107/S0108768199015086 ↗
9. 10.1107/S090904950801843810.1107/S0909049508018438 ↗
10. 10.1107/S205252061402290210.1107/S2052520614022902 ↗
11. 10.1063/1.296926010.1063/1.2969260 ↗
12. 2021
13. 10.1107/S002188987901178X10.1107/S002188987901178X ↗
14. 10.1107/S002188981300353110.1107/S0021889813003531 ↗
15. 10.1017/S088571561900081210.1017/S0885715619000812 ↗
16. 10.1016/0927-0256(96)00008-010.1016/0927-0256(96)00008-0 ↗
17. 10.1002/jcc.2315310.1002/jcc.23153 ↗
18. 10.1107/S002188981101462210.1107/S0021889811014622 ↗
19. 10.1107/S205252061600395410.1107/S2052520616003954 ↗
20. 10.1021/ar00172a00510.1021/ar00172a005 ↗
21. 10.1017/S088571561400051710.1017/S0885715614000517 ↗
22. The pharmacological activity of dl-alpha, alpha-dihenyl, gamma-dimethylaminovaleramide (Centrine)
23. Speeter, M. E. (1953). “Diphenyl-dimethyl-aminovaleramide,” U.S. Patent 2,647,926.
24. 10.1186/1758-2946-3-3310.1186/1758-2946-3-33 ↗
25. 10.3749/canmin.46.5.150110.3749/canmin.46.5.1501 ↗
26. Christie, G. J. and Buckwalter, F. H. (1975). “Anesthetic compositions,” U.S. Patent 3,896,221.
27. Crystal Impact - Dr. H. Putz & Dr. K. Brandenburg. (2022). Diamond - Crystal and Molecular Structure Visualization. Kreuzherrenstr. 102, 53227 Bonn, Germany. Available at: https://www.crystalimpact.de/diamond.
28. 10.1007/BF0054909610.1007/BF00549096 ↗
29. 10.1021/ci049780b10.1021/ci049780b ↗
30. 10.1017/S088571561800082910.1017/S0885715618000829 ↗
31. A new law of crystal morphology extending the law of Bravais
32. 10.1093/nar/gky103310.1093/nar/gky1033 ↗
33. Turner · 2017
34. 10.1107/S002188986800508X10.1107/S002188986800508X ↗
35. 10.1002/wcms.136010.1002/wcms.1360 ↗
36. 10.1107/S160057671901409210.1107/S1600576719014092 ↗
37. 10.1107/S205252061800233010.1107/S2052520618002330 ↗
38. 10.1107/S002188980201523610.1107/S0021889802015236 ↗